Stilla Launches Access Program for Industry’s First Six-Color Digital PCR System
28.7.2021 19:26:00 EEST | Business Wire | Press release
Stilla Technologies, the company innovating the next generation of digital PCR solutions for life science research and molecular diagnostics, is pleased to announce the launch of its 6-Color Digital PCR Access Program which enables early access to the industry’s first Digital PCR system featuring six fluorescent channels for providing the highest multiplexing and detection capacity available on the market today. This represents a broad portfolio expansion of the Company’s original three-color naica® system and includes reagents and digital PCR consumables, automated analytical instrumentation, and turnkey visualization software. The commercial launch of the six-color naica® system is scheduled for Fall 2021.
“There is undeniable value in detecting and quantifying multiple mutations, viruses and biomarkers from a single sample. The cost versus depth tradeoffs of NGS make it impractical for the routine testing of many samples per day, while multiplex qPCR lacks the precise quantitation and exquisite sensitivity offered by digital PCR,” said Matthew Grow, PhD, Vice President Global Marketing and Commercial Operations, Stilla Technologies. “Stilla’s new six-color product offers biomedical researchers and clinicians an unprecedented level of digital multiplexing with no compromises in applications ranging from ultra-sensitive liquid biopsies and SARS-CoV-2 variant detection where rare targets are found in large sample volumes, to the absolute quantitation needed in testing such as DNA methylation, viral titering, and disease-related gene amplifications.”
Stilla is offering scientists an opportunity to experience the power and flexibility of 6-color Digital PCR by providing a range of options to drive their evaluations, including both hands-on or remote demonstrations of the naica® system. Researchers with existing qPCR or dPCR assays may request that their assays be tested using their own samples or opt to use an available 6-color assay from Stilla. On-site demos are available on a first come, first served basis.
“As biology becomes more and more complex, researchers increasingly require next-gen tools to unlock next-gen biological breakthroughs,” said Rémi Dangla, PhD, Cofounder and Chief Technology Officer, Stilla Technologies. “Stilla’s six-color Digital PCR aligns with the complexity of biological systems and provides scientists with a superior tool for accelerating biological insights to advance their research and discovery.”
Earlier this month, the United States District Court for the District of Massachusetts issued a settlement order of dismissal on a patent infringement suit brought against Stilla by Bio-Rad Laboratories. Under the terms of the agreement, Stilla Technologies will have access to certain Intellectual Property rights from Bio-Rad in the field of digital PCR, supporting Stilla’s strategy for full deployment of its dPCR product and services in key markets.
“We are highly encouraged by this outcome which demonstrates Stilla’s steadfast commitment to upholding integrity in all our operations while advancing technological innovation to accelerate research and improve human health,” added Dr. Dangla.
For more information on the Crystal Digital PCR™ Access Program, email demo@stillatechnologies.com or sign up online at: https://www.stillatechnologies.com/6-color-dpcr/.
About Stilla Technologies
Stilla Technologies is the global life sciences company providing a groundbreaking Crystal Digital PCR™ (dPCR) solution that enables researchers and clinicians to accelerate development of advanced genetic testing and molecular biology assays for a wide range of applications, including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla aims to make dPCR a lab commodity for life sciences research, therapeutics and omics with its flexible naica® system, which incorporates proprietary, cutting–edge microfluidic innovations in addition to unsurpassed customer service and application support. To learn more visit www.stillatechnologies.com and connect with Stilla on social media Twitter, LinkedIn and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005803/en/
Contact information
Heidi Creighton
heidi.creighton@stillatechnologies.com
Mobile/Text: 978-302-1198
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JTB to Acquire Asian DMC Leader EXO Travel for Accelerated Global Growth18.6.2026 05:00:00 EEST | Press release
JTB Corp. today announced that it has reached an agreement to acquire all the shares of All Wise Holdings Pte. Ltd., the operator of Bangkok-based EXO Travel Group, a leading Destination Management Companies (DMCs) in Asia. The acquisition will be made through a JTB group company in the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106801/en/ EXO Travel operates in the B2B market, primarily across Asia Pacific. For over 30 years, it has consistently maintained high customer satisfaction based on trust, achievements and high-quality service. The company has a strong brand presence in the affluent markets of Europe, North America and Australia, where the trust of partner companies contributes significantly to its value. Additionally, EXO Travel leverages its extensive network of destinations in Asia Pacific to develop strong products and adapt flexibly to changing customer needs. EXO Travel's unique
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 02:01:00 EEST | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together, the companies will aim to develop a novel, tumour-selective therapeutic targeting a solid tumour antigen expressed across multiple difficult-to-treat cancer types. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615992992/en/ “Partnering with LG Chem represents a very important moment for LabGenius and provides further validation of our platform’s ability to design highly optimised multispecific antibodies,”said Dr. James Field, CEO of LabGenius. “We welcome this opp
Joe Vernachio Named President of SOREL18.6.2026 01:00:00 EEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 23:30:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 23:05:00 EEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom